Metagenomi Therapeutics Inc
Company Profile
Business description
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
Contact
5959 Horton Street
7th Floor
EmeryvilleCA94608
USAT: +1 510 871-4880
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
118
Stocks News & Analysis
stocks
Chart of the Week: BHP’s growth story faces a reality check
stocks
3 best ASX growth stocks to buy for the long term
stocks
The ASX data center stock flying under the radar
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,036.90 | 13.00 | -0.14% |
| CAC 40 | 8,377.86 | 4.57 | -0.05% |
| DAX 40 | 24,915.49 | 84.04 | -0.34% |
| Dow JONES (US) | 52,716.34 | 57.70 | 0.11% |
| FTSE 100 | 10,572.24 | 56.32 | 0.54% |
| HKSE | 25,008.60 | 327.50 | 1.33% |
| NASDAQ | 26,042.27 | 226.96 | -0.86% |
| Nikkei 225 | 66,835.54 | 1,915.97 | -2.79% |
| NZX 50 Index | 13,614.78 | 20.29 | -0.15% |
| S&P 500 | 7,552.20 | 20.20 | -0.27% |
| S&P/ASX 200 | 8,840.70 | 15.50 | -0.18% |
| SSE Composite Index | 3,882.41 | 73.17 | -1.85% |